01 Sep 2022
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211135
29 Mar 2021
// BUSINESSWIRE
29 Mar 2021
// BUSINESSWIRE
https://www.businesswire.com/news/home/20210329005176/en/Bayer-Announces-Publication-of-Phase-IV-Adempas%C2%AE-riociguat-Data-in-The-Lancet-Respiratory-Medicine
20 Oct 2020
// FIRSTWORDPHARMA
07 Sep 2020
// BIOSPACE
https://www.biospace.com/article/releases/bayer-phase-iv-study-met-its-primary-endpoint-in-pah-patients-who-had-transitioned-to-adempas-riociguat-after-insufficient-response-to-pde5-inhibitors-/
14 Jul 2018
// Carly Helfand FIERCE PHARMA
https://www.fiercepharma.com/marketing/adempas-maker-bayer-connects-hypertension-patients-new-mentoring-group